Fernando Vieira

CEO | ALS TDI

Dr. Fernando V. Vieira, M.D., is the long-time Chief Executive Officer and Chief Scientific Officer of the ALS Therapy Development Institute. A physician-scientist and engineer, he has led ALS TDI’s research efforts since 2001. Under his direction, multidisciplinary teams at ALS TDI have discovered and optimized multiple experimental therapies and brought them into human clinical trials. Dr. Vieira’s work spans basic biology to translational research: his lab pioneered better animal models of ALS and made fundamental discoveries about genetic forms of the disease (for example, mutations in SOD1 and C9orf72).

​

He currently co-leads the ALS Research Collaborative (ARC) Study, a nationwide initiative with over 1,000 participants. Through ARC, Dr. Vieira’s team is developing new biomarkers and digital outcome measures to more accurately track ALS progression. Trained at Harvard Medical School and the University of Florida, Vieira remains driven by the mission to discover and advance effective treatment for ALS. His leadership reflects decades of commitment: every project he oversees is aimed at slowing, stopping or reversing ALS for patients worldwide.